Ascension® MCP Post-Approval Study

Inclusion Criteria:

• Indications consistent with the FDA approved Indications For Use: Index, long, ring, orsmall finger metacarpophalangeal (MCP) joints that exhibit symptoms of pain, limitedmotion, or inadequate bony alignment (i.e., subluxation/dislocation) secondary toarticular destruction or degenerative disease related to rheumatoid arthritis, systemiclupus erythematosus, osteoarthritis, or post-traumatic arthritis where soft tissuereconstruction can provide adequate stabilization;

• Willing to participate in the study;

• Signed an Informed Consent Form

• The means and ability to return for all required study visits; and

• Are not transient.

Exclusion Criteria: Patients who have any of the following contraindications will be excluded from the study:

• Inadequate bone stock at the implantation site;

• Active infection in the MCP joint;

• Nonfunctioning and irreparable MCP musculotendinous system;

• Physical interference with or by other prostheses during implantation or use;

• Procedures requiring modification of the prosthesis; or

• Skin, bone, circulatory and/or neurological deficiency at the implantation site.